Cargando…

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI

Protein-coding variants in the GBA gene modulate susceptibility and progression in ~10% of patients with Parkinson’s disease (PD). GBA encodes the β-glucocerebrosidase enzyme that hydrolyzes glucosylceramide. We hypothesized that GBA mutations will lead to glucosylceramide accumulation in cerebrospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huh, Young Eun, Park, Hyejung, Chiang, Ming Sum Ruby, Tuncali, Idil, Liu, Ganqiang, Locascio, Joseph J., Shirvan, Julia, Hutten, Samantha J., Rotunno, Melissa S., Viel, Catherine, Shihabuddin, Lamya S., Wang, Bing, Sardi, Sergio Pablo, Scherzer, Clemens R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608962/ https://www.ncbi.nlm.nih.gov/pubmed/34811369 http://dx.doi.org/10.1038/s41531-021-00241-3

Ejemplares similares

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

No evidence for substrate accumulation in Parkinson brains with GBA mutations
por: Gegg, Matthew E., et al.
Publicado: (2015)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease
por: Rotunno, Melissa S., et al.
Publicado: (2020)

Accumulation of Glucosylceramide in the Absence of the Beta-Glucosidase GBA2 Alters Cytoskeletal Dynamics
por: Raju, Diana, et al.
Publicado: (2015)

Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease
por: Dodge, James C., et al.
Publicado: (2022)

Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation
por: Clarke, Jennifer, et al.
Publicado: (2021)

A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson’s disease
por: Stoker, Thomas B, et al.
Publicado: (2020)

Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease
por: Stoker, Thomas B, et al.
Publicado: (2020)

GBA1-dependent membrane glucosylceramide reprogramming promotes liver cancer metastasis via activation of the Wnt/β-catenin signalling pathway
por: Qiu, Zhidong, et al.
Publicado: (2022)

Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis
por: Dodge, James C., et al.
Publicado: (2021)

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
por: Huh, Young Eun, et al.
Publicado: (2023)

Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease
por: Rockenstein, Edward, et al.
Publicado: (2016)

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
por: Baccam, Gabriel C., et al.
Publicado: (2022)

The Prejudice towards People with Mental Illness (PPMI) scale: structure and validity
por: Kenny, Amanda, et al.
Publicado: (2018)

Predicting miRNA-disease associations based on PPMI and attention network
por: Xie, Xuping, et al.
Publicado: (2023)

GBA and APOE Impact Cognitive Decline in Parkinson’s Disease: A 10-Year Population-Based Study
por: Szwedo, Aleksandra A., et al.
Publicado: (2022)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy
por: Van Alstyne, Meaghan, et al.
Publicado: (2018)

Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
por: Thaler, Avner, et al.
Publicado: (2021)

Synthesis and Biological Properties of Fungal Glucosylceramide
por: Del Poeta, Maurizio, et al.
Publicado: (2014)

Defining the glucosylceramide population of C. elegans
por: Xatse, Mark A., et al.
Publicado: (2023)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Extrastriatal (123)I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
por: Mihaescu, Alexander S., et al.
Publicado: (2022)

Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
por: Li, Hongyu, et al.
Publicado: (2018)

The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD
por: Straniero, Letizia, et al.
Publicado: (2020)

The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
por: Pradas, Eddie, et al.
Publicado: (2023)

Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease
por: Karayel, Ozge, et al.
Publicado: (2022)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

MAO-B Polymorphism Associated with Progression in a Chinese Parkinson's Disease Cohort but Not in the PPMI Cohort
por: Cui, Shi-Shuang, et al.
Publicado: (2022)

Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort
por: Jeong, Eun Hye, et al.
Publicado: (2023)

Ceramides and glucosylceramides are independent antagonists of insulin action
por: Chavez, Jose A, et al.
Publicado: (2012)

Correction: Synthesis and Biological Properties of Fungal Glucosylceramide
por: Del Poeta, Maurizio, et al.
Publicado: (2015)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

A test-retest study on Parkinson's PPMI dataset yields statistically significant white matter fascicles
por: Cousineau, Martin, et al.
Publicado: (2017)

Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers: Analysis of the PPMI data
por: Lee, Jeong Won, et al.
Publicado: (2021)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_ulou49592kq0fon6hnj514h1ol